#modernatx — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #modernatx, aggregated by home.social.
-
Today, the U.S. Food and Drug Administration approved and granted emergency use authorization ( #EUA ) for
❇️ updated #mRNA #COVID19 #vaccines (2024-2025 formula)
to include a monovalent (single) component that corresponds to the Omicron variant #KP2 strain of SARS-CoV-2.
The mRNA COVID-19 vaccines have been updated with this formula to more closely target currently circulating variants and provide better protection against serious consequences of COVID-19,
including hospitalization and death.Today’s actions relate to updated mRNA COVID-19 vaccines manufactured by #ModernaTX Inc. and #Pfizer Inc.
In early June, the FDA advised manufacturers of licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 formula) should be monovalent JN.1 vaccines.
Based on the further evolution of SARS-CoV-2 and a rise in cases of COVID-19, the agency subsequently determined and advised manufacturers that the preferred JN.1-lineage for the COVID-19 vaccines (2024-2025 formula) is the KP.2 strain, if feasible.
https://www.fda.gov/news-events/press-announcements/fda-approves-and-authorizes-updated-mrna-covid-19-vaccines-better-protect-against-currently -
Today, the U.S. Food and Drug Administration approved and granted emergency use authorization ( #EUA ) for
❇️ updated #mRNA #COVID19 #vaccines (2024-2025 formula)
to include a monovalent (single) component that corresponds to the Omicron variant #KP2 strain of SARS-CoV-2.
The mRNA COVID-19 vaccines have been updated with this formula to more closely target currently circulating variants and provide better protection against serious consequences of COVID-19,
including hospitalization and death.Today’s actions relate to updated mRNA COVID-19 vaccines manufactured by #ModernaTX Inc. and #Pfizer Inc.
In early June, the FDA advised manufacturers of licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 formula) should be monovalent JN.1 vaccines.
Based on the further evolution of SARS-CoV-2 and a rise in cases of COVID-19, the agency subsequently determined and advised manufacturers that the preferred JN.1-lineage for the COVID-19 vaccines (2024-2025 formula) is the KP.2 strain, if feasible.
https://www.fda.gov/news-events/press-announcements/fda-approves-and-authorizes-updated-mrna-covid-19-vaccines-better-protect-against-currently -
Today, the U.S. Food and Drug Administration approved and granted emergency use authorization ( #EUA ) for
❇️ updated #mRNA #COVID19 #vaccines (2024-2025 formula)
to include a monovalent (single) component that corresponds to the Omicron variant #KP2 strain of SARS-CoV-2.
The mRNA COVID-19 vaccines have been updated with this formula to more closely target currently circulating variants and provide better protection against serious consequences of COVID-19,
including hospitalization and death.Today’s actions relate to updated mRNA COVID-19 vaccines manufactured by #ModernaTX Inc. and #Pfizer Inc.
In early June, the FDA advised manufacturers of licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 formula) should be monovalent JN.1 vaccines.
Based on the further evolution of SARS-CoV-2 and a rise in cases of COVID-19, the agency subsequently determined and advised manufacturers that the preferred JN.1-lineage for the COVID-19 vaccines (2024-2025 formula) is the KP.2 strain, if feasible.
https://www.fda.gov/news-events/press-announcements/fda-approves-and-authorizes-updated-mrna-covid-19-vaccines-better-protect-against-currently -
Today, the U.S. Food and Drug Administration approved and granted emergency use authorization ( #EUA ) for
❇️ updated #mRNA #COVID19 #vaccines (2024-2025 formula)
to include a monovalent (single) component that corresponds to the Omicron variant #KP2 strain of SARS-CoV-2.
The mRNA COVID-19 vaccines have been updated with this formula to more closely target currently circulating variants and provide better protection against serious consequences of COVID-19,
including hospitalization and death.Today’s actions relate to updated mRNA COVID-19 vaccines manufactured by #ModernaTX Inc. and #Pfizer Inc.
In early June, the FDA advised manufacturers of licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 formula) should be monovalent JN.1 vaccines.
Based on the further evolution of SARS-CoV-2 and a rise in cases of COVID-19, the agency subsequently determined and advised manufacturers that the preferred JN.1-lineage for the COVID-19 vaccines (2024-2025 formula) is the KP.2 strain, if feasible.
https://www.fda.gov/news-events/press-announcements/fda-approves-and-authorizes-updated-mrna-covid-19-vaccines-better-protect-against-currently